Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally.
Limited growth with imperfect balance sheet.
Share Price & News
How has Bellicum Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BPX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BPX underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: BPX underperformed the German Market which returned -17.7% over the past year.
Price Volatility Vs. Market
How volatile is Bellicum Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Bellicum Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Bellicum Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bellicum Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of BPX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Bellicum Pharmaceuticals regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Bellicum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BPX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BPX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BPX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BPX's revenue (43.1% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: BPX's revenue (43.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BPX's Return on Equity is forecast to be high in 3 years time
How has Bellicum Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BPX is currently unprofitable.
Growing Profit Margin: BPX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BPX is unprofitable, and losses have increased over the past 5 years at a rate of -7.2% per year.
Accelerating Growth: Unable to compare BPX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: BPX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Bellicum Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: BPX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BPX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BPX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BPX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: BPX has a low level of unsold assets or inventory.
Debt Coverage by Assets: BPX has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BPX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BPX has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -18.6% each year.
What is Bellicum Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BPX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BPX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BPX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BPX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BPX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Fair (50yo)
Mr. Richard A. Fair, also known as Rick, serves as Director of Clovis Oncology, Inc since October 11, 2018.served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Inc. since January 31 ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD3.28M) is above average for companies of similar size in the German market ($USD432.27K).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
|Chief Legal & Strategy Officer and Corporate Secretary||1.92yrs||US$1.15m||0.021% $4.6k|
|Chief Financial Officer||1.33yrs||no data||no data|
|Director||0.25yr||no data||no data|
|Executive Vice President of Technical Operations||4.5yrs||US$1.05m||0.014% $3.0k|
|Head of Research & Senior VP||1.08yrs||no data||0.014% $3.1k|
Experienced Management: BPX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Director||0.25yr||no data||no data|
|Independent Director||4.75yrs||US$124.47k||no data|
|Chairman of the Board||5.33yrs||US$145.51k||no data|
|Independent Director||3.92yrs||US$103.73k||no data|
|Independent Director||5.33yrs||US$128.79k||no data|
|Member of Scientific & Clinical Advisory Board||1.08yrs||no data||0.18% $39.6k|
|Independent Director||5.5yrs||US$125.66k||no data|
|Independent Director||1.33yrs||US$136.99k||no data|
|Member of Scientific & Clinical Advisory Board||1.08yrs||no data||no data|
Experienced Board: BPX's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BPX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.4%.
Bellicum Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Bellicum Pharmaceuticals, Inc.
- Ticker: BPX
- Exchange: DB
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$23.776m
- Listing Market Cap: US$21.636m
- Shares outstanding: 5.05m
- Website: https://www.bellicum.com
Number of Employees
- Bellicum Pharmaceuticals, Inc.
- Life Science Plaza
- Suite 800
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BLCM||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2014|
|BPX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2014|
|0HMS||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Dec 2014|
|BPX||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Dec 2014|
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/01 01:45|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.